ImmuPharma plc (IMMPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ImmuPharma plc (IMMPF) trades at $0.09 with AI Score 44/100 (Grade C). ImmuPharma plc is a biopharmaceutical company focused on discovering and developing peptide-based therapeutics for autoimmune, inflammatory, and anti-infective diseases. Market cap: $28.34M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for IMMPF: IMMPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMMPF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMMPF: the 1 perspectives are evenly split.
How is this calculated? →ImmuPharma plc (IMMPF) Healthcare & Pipeline Overview
ImmuPharma plc is a biopharmaceutical company specializing in peptide-based therapeutics, with a focus on autoimmunity and inflammation. Its lead candidate, Lupuzor, targeting lupus, is currently in Phase III trials. The company also develops treatments for fungal infections and antibacterial solutions, operating within the competitive biotechnology sector.
What Is the Investment Thesis for IMMPF?
ImmuPharma's investment thesis hinges on the successful completion and commercialization of Lupuzor, their lead drug candidate for lupus, currently in Phase III trials. Positive trial results could drive significant value, given the substantial market for lupus treatments. The company's pipeline of peptide-based therapeutics, including BioAMB and BioCin, offers additional potential revenue streams. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and securing funding for ongoing research and development. With a market capitalization of $28.34M and a negative P/E ratio of -6.60, the company's financial performance is closely tied to the success of its clinical programs. Upcoming data releases from the Phase III trial of Lupuzor will be a key catalyst to watch.
Based on FMP financials and quantitative analysis
IMMPF Key Highlights
- Market capitalization of $28.34M reflects the company's current valuation in the biotechnology sector.
- Phase III clinical trial for Lupuzor represents a critical milestone with potential for significant market impact.
- Collaboration with Centre National de la Recherche Scientifique expands the company's research capabilities in diabetes therapeutics.
- Negative P/E ratio of -6.60 indicates that the company is currently not profitable, common for development-stage biopharmaceutical companies.
- Beta of 1.41 suggests that the stock is more volatile than the market average.
Who Are IMMPF's Competitors?
IMMPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACOGF Alpha Cognition Inc. | $5.72 | +0.00% | $35.66M | 50 |
| CHBRF Chill Brands Group PLC | $0.05 | +48.84% | $24.45M | 38 |
| DMTTF Small Pharma Inc. | $0.11 | -9.69% | $37.51M | 44 |
| EMMLF OKYO Pharma Limited | $0.01 | +0.00% | $22.73M | 44 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.34M | 63 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMMPF's Key Strengths?
- Proprietary peptide-based drug development platform.
- Lead product candidate, Lupuzor, in Phase III clinical trials.
- Focus on unmet medical needs in autoimmunity, inflammation, and anti-infectives.
- Collaboration with Centre National de la Recherche Scientifique.
What Are IMMPF's Weaknesses?
- Limited financial resources.
- Dependence on the success of Lupuzor.
- Small number of employees.
- OTC market listing.
What Could Drive IMMPF Stock Higher?
- Data releases from the Phase III clinical trial of Lupuzor.
- Potential regulatory submissions for Lupuzor.
- Advancement of BioAMB and BioCin through preclinical and clinical development.
- Securing strategic partnerships and licensing agreements.
- Expansion of diabetes therapeutics pipeline through collaboration with Centre National de la Recherche Scientifique.
What Are the Key Risks for IMMPF?
- Failure of Lupuzor Phase III clinical trial.
- Regulatory rejection of Lupuzor.
- Competition from larger pharmaceutical companies.
- Funding challenges for research and development.
- Risks associated with OTC market listing.
What Are the Growth Opportunities for IMMPF?
- Successful completion and commercialization of Lupuzor for lupus treatment: The global lupus therapeutics market is projected to reach billions of dollars. Positive Phase III trial results and subsequent regulatory approval could provide ImmuPharma with a significant revenue stream. Timeline: Anticipated data releases and regulatory submissions within the next 12-24 months.
- Development and commercialization of BioAMB for fungal infections: The market for antifungal drugs is substantial, driven by increasing incidence of invasive fungal infections. BioAMB's peptide-based approach could offer advantages over existing treatments. Timeline: Preclinical and clinical development ongoing, with potential for market entry in 3-5 years.
- Advancement of BioCin as a novel antibacterial drug: With rising antibiotic resistance, there is a critical need for new antibacterial agents. BioCin targets high medical need cases and last-line-of-defense situations. Timeline: Preclinical and clinical development ongoing, with potential for market entry in 5-7 years.
- Expansion of diabetes therapeutics pipeline through collaboration with Centre National de la Recherche Scientifique: The diabetes market is large and growing, driven by increasing prevalence of type 1 and type 2 diabetes. Developing novel peptide-based therapies could provide ImmuPharma with a foothold in this market. Timeline: Ongoing research and development, with potential for clinical candidates in 3-5 years.
- Strategic partnerships and licensing agreements: ImmuPharma can leverage partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline products. Licensing agreements can provide upfront payments and milestone payments, as well as royalties on future sales. Timeline: Ongoing efforts to secure partnerships and licensing agreements.
What Opportunities Does IMMPF Have?
- Positive results from Lupuzor Phase III trial.
- Expansion of pipeline through research and development.
- Strategic partnerships and licensing agreements.
- Growing market for autoimmune disease treatments.
What Threats Does IMMPF Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Funding challenges.
What Are IMMPF's Competitive Advantages?
- Proprietary peptide-based drug development platform.
- Patent protection for drug candidates.
- Clinical trial data demonstrating safety and efficacy.
- Strategic collaborations with research institutions.
What Does IMMPF Do?
Founded in 1999 and headquartered in London, ImmuPharma plc is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutics. The company focuses on addressing unmet medical needs in autoimmunity, inflammation, and anti-infectives. Their lead product candidate, Lupuzor, is an autophagy immunomodulator currently in Phase III clinical trials for the treatment of lupus, a chronic autoimmune inflammatory disease affecting millions worldwide. Beyond Lupuzor, ImmuPharma is developing BioAMB, a peptide-based drug targeting Amphotericin-B formulations for fungal infections, and BioCin, a peptide-based antibacterial drug for high medical need cases. ImmuPharma collaborates with Centre National de la Recherche Scientifique for developing a peptide technology platform to treat diabetes, exploring glucagon-like peptide-1 agonists and glucagon antagonists. They also have a license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma's strategy involves identifying and developing novel peptide-based therapies to improve patient outcomes in areas with significant unmet medical needs.
What Products and Services Does IMMPF Offer?
- Discovers and develops peptide-based therapeutics.
- Focuses on therapies for autoimmunity and inflammation.
- Develops anti-infective drugs.
- Conducts clinical trials to evaluate drug candidates.
- Collaborates with research institutions and pharmaceutical companies.
- Seeks regulatory approvals for its products.
How Does IMMPF Make Money?
- Develops and patents peptide-based drug candidates.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA and EMA.
- Commercializes approved drugs directly or through partnerships.
What Industry Does IMMPF Operate In?
ImmuPharma operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The autoimmune disease market, particularly for lupus treatments, is a growing area of focus. Competition includes companies developing novel biologics and small molecule drugs. ImmuPharma's peptide-based approach offers a differentiated strategy, but the company faces challenges from larger, more established players with greater resources. The biotechnology industry is driven by innovation, clinical trial outcomes, and regulatory approvals.
Who Are IMMPF's Key Customers?
- Patients suffering from autoimmune diseases like lupus.
- Patients with fungal infections.
- Patients requiring antibacterial treatments.
- Healthcare providers prescribing ImmuPharma's drugs.
IMMPF Valuation & Market Position
With a $28.34M market cap, ImmuPharma plc sits in the micro-cap segment of the market. Relative to its peer group, IMMPF's quantitative score of 44/100 is roughly in line with the peer average of 48/100.
Key Financial Metrics
Its free cash flow yield is -16.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.52 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.5%, the inverse of the P/E and a quick read on earnings relative to price.
IMMPF Financials
Bull Case vs Bear Case
Bull Case
- Proprietary peptide-based drug development platform.
- Lead product candidate, Lupuzor, in Phase III clinical trials.
- Focus on unmet medical needs in autoimmunity, inflammation, and anti-infectives.
- Collaboration with Centre National de la Recherche Scientifique.
Bear Case
- Limited financial resources.
- Dependence on the success of Lupuzor.
- Small number of employees.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
IMMPF Latest News
-
ImmuPharma focused on securing P140 licensing deal in 2026
proactiveinvestors.co.uk · May 27, 2026
IMMPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMMPF.
Price Targets
Wall Street price target analysis for IMMPF.
IMMPF MoonshotScore
What does this score mean?
The MoonshotScore rates IMMPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Timothy Paul McCarthy XIV, FCCA, MBA
CEO
Timothy Paul McCarthy XIV is a seasoned executive with FCCA and MBA credentials. His background includes extensive experience in financial management, corporate strategy, and leadership roles within various organizations. He has a proven track record of driving growth and improving operational efficiency. His expertise spans across multiple industries, providing him with a broad perspective on business challenges and opportunities.
Track Record: As CEO of ImmuPharma plc, Timothy Paul McCarthy XIV oversees the company's strategic direction and operational execution. He is responsible for guiding the development and commercialization of the company's pipeline products, including Lupuzor. Under his leadership, ImmuPharma has focused on advancing its clinical programs and securing partnerships to support its growth initiatives.
IMMPF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ImmuPharma plc may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, which increases the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and oversight, resulting in less transparency and potentially higher volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher volatility compared to stocks listed on major exchanges.
- Increased risk of fraud or mismanagement.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's pipeline and clinical trial data.
- Check for any legal or regulatory issues.
- Monitor trading volume and price fluctuations.
- Consult with a financial advisor.
- Phase III clinical trial for Lupuzor suggests a degree of scientific validation.
- Collaboration with Centre National de la Recherche Scientifique indicates research credibility.
- Development of peptide-based therapeutics addresses unmet medical needs.
- Presence of a CEO with FCCA and MBA credentials.
- Founded in 1999, indicating some operational history.
ImmuPharma plc Healthcare Stock: Key Questions Answered
What does ImmuPharma plc do?
ImmuPharma plc is a biopharmaceutical company focused on discovering and developing peptide-based therapeutics for autoimmune, inflammatory, and anti-infective diseases. Their lead product candidate, Lupuzor, is currently in Phase III clinical trials for the treatment of lupus, a chronic autoimmune inflammatory disease. The company also develops BioAMB for fungal infections and BioCin as an antibacterial drug. ImmuPharma collaborates with research institutions like Centre National de la Recherche Scientifique to expand its pipeline and address unmet medical needs.
What are the main risks for IMMPF?
The main risks for ImmuPharma plc include the potential failure of clinical trials, particularly for Lupuzor, which is in Phase III. Regulatory hurdles and competition from larger pharmaceutical companies also pose significant challenges. Funding for ongoing research and development is a constant concern, especially given the company's OTC market listing and limited financial resources. The low liquidity and potential for price manipulation associated with OTC stocks further increase the investment risk.
What are the key factors to evaluate for IMMPF?
ImmuPharma plc (IMMPF) holds an AI score of 44/100 (low). Not financial advice.
How frequently does IMMPF data refresh on this page?
IMMPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IMMPF's recent stock price performance?
ImmuPharma plc (IMMPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary peptide-based drug development platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMMPF overvalued or undervalued right now?
Valuing ImmuPharma plc (IMMPF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IMMPF?
Before investing in ImmuPharma plc (IMMPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding IMMPF to a portfolio?
Key strength of ImmuPharma plc (IMMPF): Proprietary peptide-based drug development platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.